Beacon Therapeutics, based in London and Oxford, UK, have recently announced an investment of £96 million (€112 million) to fund the acquisition of AGTC (Applied… Read More »Beacon Therapeutics have announced the acquisition of AGTC (NASDAQ: AGTC), supported by Syncona Ltd and Oxford Science Enterprises.
FDA approval of visual gains and safety of aflibercept (8mg) were announced on August 18th, indicated for the treatment of patients with wet age-related macular… Read More »Aflibercept (8mg) has been approved for wet AMD, diabetic macular edema (DME) and diabetic retinopathy (DR).
Researchers at the Institute of Ophthalmology, University College London and Moorfields Eye Hospital have reported that biomarkers, analysed by OCT scans, have shown reduced thickness… Read More »UCL Institute of Ophthalmology and Moorfields Eye Hospital publish data on OCT scan assessing biomarkers for neurodegeneration.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 28th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »August 28th, 2023 “EURETINA-Brief”© Issue No. 277
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), an ophthalmic pharmaceutical company based in California, and the Choroideremia Research Foundation (CRF), a non-for-profit patient organisation focused on the… Read More »Kiora Pharmaceuticals Inc. have announced a partnership with the Choroideremia Research Foundation for novel treatments.
Results of a biosimilar agent (SB15) of aflibercept (Eylea) have reported comparable outcomes between the generic version and the reference drug (aflibercept) for naïve neovascular… Read More »A biosimilar of aflibercept (“SB15”) indicates comparability to the reference drug for neovascular AMD.
Research conducted at Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, has reported three approaches to test novel strategies to treat a range of… Read More »Research for testing end-stage therapies for retinal degenerations for non-human primate (NHP) models.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the August 10th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »August 10th, 2023 “EURETINA-Brief”© Issue No. 276
According to the ASRS Research and Safety in Therapeutics (ReST) Committee, a small number of cases of occlusive retinal vasculitis has been observed between 7… Read More »The American Society of Retina Specialists (ASRS) has reported at least six cases of occlusive retinal vasculitis following injection of Syfovre (pegcetacoplan).
Researchers at Schulich School of Medicine and Dentistry, Western University, Ontario, Canada, reported a meta-analysis among AMD patients finding reduced incomes and reduced employment following… Read More »Research on AMD patients’ productivity and participation in the labour market.
